Whalegun
Lobbying

Ascendis Pharma's latest lobbying report covers Q2 2026, at $230K. The four quarters Q4 2025–Q3 2026 total $770K. Its first report covers Q4 2022; the issues it reports most are Pharmacy.

Ascendis Pharma

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$770K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Ascendis Pharma lobbying by quarter
Ascendis Pharma lobbying by quarter
QuarterAmountReports
Q4 2022$200K2
Q1 2023$270K2
Q2 2023$180K2
Q3 2023$190K2
Q4 2023$190K2
Q1 2024$340K2
Q2 2024$160K2
Q3 2024$120K2
Q4 2024$160K2
Q1 2025$210K2
Q2 2025$220K2
Q3 2025$230K2
Q4 2025$230K2
Q1 2026$310K2
Q2 2026$230K2
Q3 2026$00

By issue

  • Pharmacy$1.3M · 17 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Food & Drug Administration (FDA)15 reports
  • HOUSE OF REPRESENTATIVES2 reports
  • SENATE2 reports

Firms it paid

Firm
In-houseAscendis Pharma$2.3M15 quarters
Rubicon Advisors$900K15 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
07/20for Q2In-house$170K
07/20for Q2Rubicon Advisors$60K
04/23for Q1Rubicon Advisors$60K
04/17for Q1In-house$250K
01/20for Q4 2025In-house$170K
01/18for Q4 2025Rubicon Advisors$60K
25/10/21for Q3 2025Rubicon Advisors$60K
25/10/20for Q3 2025In-house$170K
25/07/21for Q2 2025In-house$160K
25/07/19for Q2 2025Rubicon Advisors$60K
25/04/21for Q1 2025Rubicon Advisors$60K
25/04/21for Q1 2025In-house$150K
25/01/21for Q4 2024Rubicon Advisors$60K
25/01/17for Q4 2024In-house$100K
24/12/19for Q4 2024In-houseUnder $5,000
24/10/22for Q3 2024In-house$60K
24/10/22for Q3 2024Rubicon Advisors$60K
24/07/21for Q2 2024In-house$100K
24/07/21for Q2 2024Rubicon Advisors$60K
24/07/17for Q2 2024Rubicon Advisors$60K